With respect to the delivery and distribution of erlotinib in EGFR-mutated NSCLC, several studies have shown important aspects of the relationship between microvessel normalization by antiangiogenic agents and drug delivery and distribution. This evidence concerns the gene EGFR and non-small cell lung carcinoma.